CA 19-9

Cancer Antigen 19-9

Q: What if my CA 19-9 is normal but I have pancreatic cancer symptoms?

A normal CA 19-9 does not exclude pancreatic cancer. About 15–20% of pancreatic cancers do not produce elevated CA 19-9, particularly in Lewis antigen-negative individuals. If symptoms are concerning, pursue diagnostic imaging regardless of CA 19-9 results.

Tumor Markers

What is Cancer Antigen 19-9?

Cancer Antigen 19-9 (CA 19-9) is a carbohydrate antigen—specifically a sialylated Lewis-a blood group antigen—that is found on the surface of certain epithelial cells and shed into the bloodstream. It was originally identified using a monoclonal antibody (1116 NS 19-9) raised against a human colon carcinoma cell line. CA 19-9 is produced by normal pancreatic and biliary ductal cells, as well as gastric, colonic, endometrial, and salivary epithelium at low levels.

CA 19-9 is the most widely used serum biomarker for pancreatic adenocarcinoma. It serves primarily as a tool for monitoring treatment response, assessing surgical resectability, and detecting disease recurrence. CA 19-9 is not recommended as a screening test for pancreatic cancer in the general population due to insufficient sensitivity and specificity. Approximately 5–10% of the population lacks the Lewis antigen and cannot synthesize CA 19-9, making the test uninformative in these individuals regardless of disease status. Biliary obstruction from any cause can markedly elevate CA 19-9, reducing its specificity.

Why It Matters

CA 19-9 is the most clinically useful serum marker for pancreatic ductal adenocarcinoma. Preoperative CA 19-9 levels help predict resectability—very high values (>1000 U/mL) often indicate unresectable or metastatic disease. Declining CA 19-9 after surgery or chemotherapy suggests treatment response, while rising levels signal disease progression or recurrence. Because CA 19-9 is also elevated in benign biliary obstruction, cholangitis, pancreatitis, and other gastrointestinal conditions, results must be interpreted alongside imaging and clinical findings.

Normal Reference Ranges

Group	Range	Unit
Adults	0–37	U/mL
Lewis antigen-negative individuals	Undetectable (test not applicable)	U/mL

Reference ranges may vary by laboratory. Always compare results to the ranges provided by your testing facility.

What High CA 19-9 Levels Mean

Common Causes

Pancreatic adenocarcinoma
Cholangiocarcinoma (bile duct cancer)
Biliary obstruction (benign or malignant)
Acute and chronic pancreatitis
Cholangitis
Colorectal cancer
Gastric cancer
Hepatocellular carcinoma
Cystic fibrosis
Liver cirrhosis

Possible Symptoms

Jaundice (yellowing of skin and eyes)
Unexplained weight loss
Abdominal or back pain
New-onset diabetes in adults over 50
Loss of appetite
Dark urine and pale stools
Nausea

What to do: Elevated CA 19-9 requires imaging (typically CT or MRI of the abdomen) to identify the underlying cause. If biliary obstruction is present, CA 19-9 should be re-measured after biliary drainage, as obstruction alone can cause marked elevation. For patients with known pancreatic cancer, serial CA 19-9 is used to monitor chemotherapy response and detect recurrence. Levels >1000 U/mL preoperatively may indicate unresectable disease. Additional workup may include endoscopic ultrasound with biopsy and cross-sectional imaging.

What Low CA 19-9 Levels Mean

Common Causes

Normal physiological state
Lewis antigen-negative phenotype (5–10% of population)
Successful cancer treatment

Possible Symptoms

No symptoms associated with low CA 19-9

What to do: Low or undetectable CA 19-9 is typically normal. In Lewis antigen-negative individuals, CA 19-9 will be undetectable regardless of disease status, and the test should not be used for monitoring. After cancer treatment, normalization of CA 19-9 is a favorable prognostic indicator, though continued surveillance with imaging remains essential.

When Is CA 19-9 Testing Recommended?

Monitoring treatment response in pancreatic cancer
Assessing surgical resectability of pancreatic tumors
Surveillance for recurrence after pancreatic cancer surgery
Helping differentiate malignant from benign pancreatic cysts
Monitoring cholangiocarcinoma treatment

Frequently Asked Questions

No. CA 19-9 is not recommended for screening in asymptomatic individuals. Its sensitivity is only about 80% for pancreatic cancer, and many benign conditions cause false elevations. Additionally, 5–10% of people are Lewis antigen-negative and will have undetectable CA 19-9 even with advanced disease. Screening would produce too many false positives and miss some true cases.

Benign conditions such as biliary obstruction, pancreatitis, cholangitis, liver cirrhosis, and even cystic fibrosis can elevate CA 19-9 without malignancy. Mild elevations (<100 U/mL) are frequently benign. If the elevation persists after resolving potential benign causes, closer follow-up with repeat testing and imaging may be warranted.

A normal CA 19-9 does not exclude pancreatic cancer. About 15–20% of pancreatic cancers do not produce elevated CA 19-9, particularly in Lewis antigen-negative individuals. If symptoms are concerning, pursue diagnostic imaging regardless of CA 19-9 results.

Related Biomarkers

CA-125Cancer Antigen 125 CEACarcinoembryonic Antigen

Want your CA 19-9 levels analyzed?

Upload your lab results for an instant AI-powered breakdown of all your biomarkers.

Upload Lab Results →

Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Reference ranges may vary between laboratories. Always consult your healthcare provider for interpretation of your specific test results.